Evidence map›Paper›PMID 38890191›Full record

ReviewAAPS PharmSciTech2024

Stealth Nanocarriers in Cancer Therapy: a Comprehensive Review of Design, Functionality, and Clinical Applications.

Mohamed J Saadh, Mohammed Ahmed Mustafa, Ashwani Kumar, Hassan Thoulfikar A Alamir, Abhishek Kumar, Shaymaa Abdulhameed Khudair, Ahmed Faisal, Mahmood Hasen Shuhata Alubiady, Sarah Salah Jalal, Shafik Shaker Shafik and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Engineered MoSNanomaterials (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mohamed J SaadhFaculty of Pharmacy, Middle East University, Amman, 11831, Jordan. msaadeh@meu.edu.jo.ORCID http://orcid.org/0009-0009-7460-6359
Mohammed Ahmed MustafaDepartment of Medical Laboratory Technology, University of Imam Jaafar AL-Sadiq, Baghdad, Iraq.
Ashwani KumarDepartment of Life Sciences, School of Sciences, Jain (Deemed-to-be) University, Bengaluru, Karnataka, India.
Hassan Thoulfikar A AlamirFaculty of Pharmacy, Department of Pharmaceutics, University of Al-Ameed, Najaf, Iraq.
Abhishek KumarSchool of Pharmacy-Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University, Gangoh, 247341, Uttar Pradesh, India.
Shaymaa Abdulhameed KhudairDepartment of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq.
Ahmed FaisalDepartment of Pharmacy, Al-Noor University College, Nineveh, Iraq.
Mahmood Hasen Shuhata AlubiadyDepartment of Pharmacy, Al-Hadi University College, Baghdad, 10011, Iraq.
Sarah Salah JalalCollege of Pharmacy, National University of Science and Technology, Nasiriyah, Dhi Qar, Iraq.
Shafik Shaker ShafikExperimental Nuclear Radiation Group, Scientific Research Center, Al-Ayen University, Thi-Qar, Iraq.
Irfan AhmadDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Faeza A F KhryFaculty of pharmacy, department of pharmaceutics, Al-Esraa University, Baghdad, Iraq.
Munther Kadhim AbosaodaCollege of Technical Engineering, The Islamic University, Najaf, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology has significantly transformed cancer treatment by introducing innovative methods for delivering drugs effectively. This literature review provided an in-depth analysis of the role of nanocarriers in cancer therapy, with a particular focus on the critical concept of the 'stealth effect.' The stealth effect refers to the ability of nanocarriers to evade the immune system and overcome physiological barriers. The review investigated the design and composition of various nanocarriers, such as liposomes, micelles, and inorganic nanoparticles, highlighting the importance of surface modifications and functionalization. The complex interaction between the immune system, opsonization, phagocytosis, and the protein corona was examined to understand the stealth effect. The review carefully evaluated strategies to enhance the stealth effect, including surface coating with polymers, biomimetic camouflage, and targeting ligands. The in vivo behavior of stealth nanocarriers and their impact on pharmacokinetics, biodistribution, and toxicity were also systematically examined. Additionally, the review presented clinical applications, case studies of approved nanocarrier-based cancer therapies, and emerging formulations in clinical trials. Future directions and obstacles in the field, such as advancements in nanocarrier engineering, personalized nanomedicine, regulatory considerations, and ethical implications, were discussed in detail. The review concluded by summarizing key findings and emphasizing the transformative potential of stealth nanocarriers in revolutionizing cancer therapy. This review enhanced the comprehension of nanocarrier-based cancer therapies and their potential impact by providing insights into advanced studies, clinical applications, and regulatory considerations.

Indexed as

Antineoplastic AgentsDrug CarriersNanoparticlesNeoplasmsAnimalsDrug Delivery SystemsHumansLiposomesMicellesNanomedicineTissue DistributionAntineoplastic AgentsDrug CarriersLiposomesMicellescancer therapyclinical applicationsdrug deliverynanocarriersstealth effect

Identifiers

PMID38890191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.